Previsão

O preço-alvo médio dos analistas é € 19,94 (+23,85%). A mediana é € 19,94 (+23,85%).

Comprar	10
Manter	0
Vender	0

Notícias Ir para o feed de notícias

SI BONE to expand growth beyond pelvic area

SI BONE unveiled a broader medtech portfolio at the Morgan Stanley Healthcare Conference and plans to drive growth beyond sacroiliac joint treatment into spinal, trauma and interventional markets. In the second quarter, global revenue rose 15% and the base of active physicians increased 19% to about 720; adjusted EBITDA improved by roughly 180% and operating cash flow turned positive at just under $1 million. The company is accelerating product rollouts (Granite, TNT, iFuse INTRA) and plans a first spinal fusion device with an alpha launch in Q4 2024, plus one to two new products annually. Improved reimbursement should increase profitability, including new Granite DRGs from October 1, 2026, and potential NTAP support for a third Breakthrough Device from October 1, 2027. » Mais em de.investing.com
SI-BONE Q1 2026: significant profit jump and growing physician base

SI-BONE reported Q1 2026 revenue of $52.6m (+11.2%) and adjusted EBITDA of $2.5m, a 440% improvement year-over-year. The active physician base rose 17.3% to a record 1,650 doctors, and procedure volume in the US grew by 8%. The company raised its full-year revenue guidance to $230–233m and expects a gross margin of around 79%; cash stands at $144.7m. Despite progress, a net loss of $4.3m remains, and management highlights risks related to market penetration, reimbursements, and production capacity. » Mais em de.investing.com
Si-Bone beats EPS forecast for Q1 2026 and raises annual outlook

Si-Bone reported Q1 2026 earnings per share of -$0.10, beating the consensus expectation of -$0.19. Revenue was $52.6 million (+11.2% y/y), missing the estimate of $52.85 million only slightly. Gross margin remained high at 79.8%, adjusted EBITDA rose to $2.5 million (+440%), and the stock climbed 1.79% in after-hours trading. Management raised the full-year guidance and expects accelerated revenue growth. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2021, SI-BONE Inc já distribuiu € 0,12 em dividendos. A última distribuição ocorreu em julho de 2021.

Dados financeiros da empresa

No último trimestre, SI-BONE Inc registou receitas de € 49,08 mi e um ganho líquido de -€ 3,58 mi

(EUR)	junho de 2026	YoY
Receitas	49,08 mi	18,95%
Ganho bruto	39,03 mi	18,55%
Ganho líquido	-3,58 mi	31,37%
EBITDA	-2,74 mi	21,58%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 706,73 mi
Número de ações	44,35 mi
Máximo/mínimo de 52 semanas	€ 18,98 - € 9,95
Dividendos	Não
Beta	0,71
PER (PE Ratio)	-54,09
PEG (PEG Ratio)	-0,97
P/VC (PB Ratio)	4,46
P/V (PS Ratio)	3,82

Perfil da empresa

SI-BONE, Inc. ist ein Medizintechnikunternehmen, das implantierbare Geräte zur Lösung von Muskel-Skelett-Erkrankungen der sakropelvinen Anatomie in den Vereinigten Staaten und international entwickelt. Das Unternehmen bietet iFuse an, ein minimal-invasives chirurgisches Implantatsystem zur Behandlung von Dysfunktion und Degeneration des Iliosakralgelenks, von Deformitäten bei Erwachsenen und von traumatischen Beckenringfrakturen. Das Unternehmen bietet auch iFuse-3D an, ein Titanimplantat, das den dreieckigen Querschnitt des iFuse-Implantats mit der proprietären 3D-gedruckten porösen Oberfläche und dem gefensterten Design kombiniert, sowie iFuse-TORQ, eine Reihe von 3D-gedruckten Gewindeimplantaten, die für die Behandlung von Beckenfrakturen und für die minimalinvasive Iliosakralgelenkfusion entwickelt wurden. Das Unternehmen vertreibt seine Produkte in erster Linie über einen Direktvertrieb sowie über Vertriebshändler. Das Unternehmen wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Santa Clara, Kalifornien.

Nome	SI-BONE Inc
CEO	Laura A. Francis
Sede	Santa Clara, ca EUA
Site	si-bone.com
Setor	Bens de consumo não essenciais
Indústria	Bens de consumo duradouros
Entrada em bolsa	17/10/2018
Colaboradores	376